uniQure N.V. logo
uniQure N.V. QURE
$ 48.62 3.31%
report update icon

Annual report 2025
added 07-29-2026

uniQure N.V. Income Statement 2025-2011 | QURE

Brief overview of financial performance at uniQure N.V.

This overview is based on financial performance over the past five years. Revenue reported by uniQure N.V. was 37.5 million dollars at the beginning of the period and 16.1 million dollars at the end. The five-year change reached −57.1%, while CAGR stood at −15.6%. The business finished the period with a smaller revenue base.

At the gross-profit level, the result moved from −38.4 million dollars to 14.4 million dollars, a change of +137.5%. Cost of revenue developed more favorably than sales, supporting gross profitability. Comparing the endpoints gives gross margins of −102.4% and 89.5%. The margin shift points to a more favorable sales-and-cost structure.

EBITDA changed from −$115 million to −$171 million (−48.6%). EBITDA moved broadly in line with revenue. EBITDA margin moved from −306% to −1059.7%. Cost pressure reduced operating profitability.

The net financial result changed from −$125 million to −$199 million. The negative result deepened, showing weaker final efficiency.

The five-year change in capitalization reached −60.2%: from $1.6 billion to $626 million. Market expectations deteriorated over the period.

What the figures show

Signs of deterioration dominate the five-year picture. The financial profile benefits from better sales economics. Caution is warranted because of a weaker final result, limited revenue growth and declining capitalization. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement uniQure N.V.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

626 M 587 M 322 M 978 M 830 M 1.57 B 2.37 B 1.18 B 526 M 138 M 403 M 360 M - - -

Shares

57.5 M 48.6 M 47.7 M 46.7 M 46 M 44.5 M 40 M 35.6 M 27 M 25 M 22.1 M 17.1 M - - -

Historical Prices

10.9 12.1 6.75 20.9 18.1 35.4 57.6 34.2 18.5 5.52 18.2 21 - - -

Net Income

-199 M -240 M -308 M -127 M 330 M -125 M -124 M -83.3 M -79.3 M -73.4 M -78.1 M -45 M -37 M -19.5 M -22.4 M

Revenue

16.1 M 27.1 M 15.8 M 106 M 524 M 37.5 M 7.28 M 11.3 M 13.1 M 25.1 M 10.3 M 5.7 M 4.06 M - -

Cost of Revenue

1.69 M 1.27 M 65 K 1.25 M 25 M 75.9 M 1.65 M 1.2 M 817 K 1.35 M 31.4 M 27.7 M - - -

Gross Profit

- - - - - - - - - - 9.67 M 5.7 M 2.96 M - -

Operating Income

-185 M -184 M -283 M -143 M 311 M -125 M -121 M -88.2 M -71.3 M -71.9 M -71.2 M -53.7 M - - -

Interest Expense

10.9 M - 41.6 M 11.7 M 7.47 M 3.82 M 3.81 M 2.16 M 2.23 M 2.17 M 2.57 M 2.02 M - - -

EBITDA

-171 M -172 M -271 M -135 M 317 M -115 M -114 M -75.8 M -63.8 M -65.9 M -57.2 M -39.3 M -30.4 M -18 M -21.4 M

Operating Expenses

- - - - - - 128 M 99.5 M 84.4 M - 71.8 M 46.8 M 34.1 M - -

General and Administrative Expenses

65.5 M 52.7 M 74.6 M 55.1 M 56.3 M 42.6 M 33.5 M 25.3 M 24.6 M - - - - 6.04 M -

All numbers in USD currency

Quarterly Income Statement uniQure N.V.

2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

62.7 M 62.3 M 58.5 M 54.8 M 53.1 M 49 M 48.7 M 48.6 M 48.4 M 47.8 M 47.8 M 47.6 M 47.4 M 47 M 46.8 M 46.7 M 46.6 M 46.3 M 46.2 M 46 M 45.5 M 44.8 M 44.5 M 44.4 M 44.3 M 43.7 M 40.7 M 37.8 M 37.7 M 37.4 M 37.2 M 36.2 M 31.7 M 31.3 M 25.6 M 25.6 M 25.4 M 25.3 M 25.1 M 25.1 M 24.7 M 24.3 M - - - - - - - - - - - - - - - - - - -

Net Income

-53.5 M - -80.5 M -37.7 M -43.6 M - -44.4 M -56.3 M -65.6 M - -89.6 M -68.5 M -77.2 M - -47.9 M -39.1 M -46.7 M - 321 M 358 M -41.6 M - -124 M -70.6 M -28 M - -82.8 M -59.2 M -27.8 M - -61.4 M -39.4 M -18.8 M - -51.8 M -41.5 M -20.3 M - -15.3 M -21.1 M -22.3 M - - - - - - - - - - - - - - - - - - - -

Revenue

3.56 M - 3.7 M 5.26 M 1.57 M - 2.29 M 11.1 M 8.48 M - 1.41 M 2.42 M 5.32 M - 1.45 M 497 K 1.79 M - 1.99 M 464 M 454 K - 1.79 M 1.54 M 104 K - 1.05 M 2.47 M 1.14 M - 3.15 M 3.05 M 3.48 M - 2.26 M 4.94 M 3.32 M - 7.22 M 4.45 M 4.3 M - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

219 K - 398 K 656 K 197 K - 264 K 234 K 150 K - - - - - - - - - 23.2 M 23.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-45.7 M - -51 M -43.9 M -39.3 M - -40.2 M -44 M -54.2 M - -81.9 M -65.1 M -74.2 M - -59.5 M -56.1 M -54.1 M - -45 M 398 M -44.5 M - -44.5 M -38.2 M -34.5 M - -31.3 M -29.3 M -27.5 M - -23.2 M -21.2 M -19.6 M - -9.28 M -19.7 M -19.7 M - -14.2 M -22.1 M -19.3 M - - - - - - - - - - - - - - - - - - - -

Interest Expense

3.77 M - -7.22 M - - - - - 16.1 M - 15.4 M 6.84 M 3.56 M - 3.07 M 2.69 M 2.52 M - 1.92 M 1.9 M 1.55 M - 942 K 970 K 975 K - 960 K 937 K 957 K - 515 K 565 K 416 K - 577 K 502 K 504 K - 507 K 549 K 629 K - - - - - - - - - - - - - - - - - - - -

EBITDA

-42.8 M - - - -34.8 M - - - -51.6 M - - - -71.6 M - -53.3 M -52 M -52 M - -39.6 M 402 M -42.6 M - -36.1 M -34.7 M -32.7 M - -26.4 M -26.1 M -25.9 M - -12.8 M -18 M -18 M - -7.58 M -15.5 M -17.9 M - -12.8 M -19.1 M -17.8 M - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - 28.6 M - 26.4 M 24.4 M 23.4 M - 25.7 M 22.3 M 23.4 M - 21.7 M 27.1 M 24 M - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

20.1 M - 19.4 M 13.5 M 10.9 M - 11.6 M 15.8 M 13.9 M - 18.1 M 21.2 M 17.8 M - 13.3 M 12.5 M 11 M - 12 M 17.3 M 12.4 M - 10.8 M 11.5 M 9.07 M - 8.93 M 7.87 M 8.07 M - 5.9 M 5.9 M 6.3 M - 5.58 M 5.41 M 6.36 M - 5.11 M 7.83 M 7.3 M - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company uniQure N.V. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.19 5.31 % $ 14.5 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.37 0.23 % $ 958 M britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BeyondSpring BeyondSpring
BYSI
$ 0.84 34.27 % $ 34.5 M usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.98 4.93 % $ 568 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.41 4.17 % $ 225 M israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Champions Oncology Champions Oncology
CSBR
$ 5.1 2.63 % $ 70.5 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.98 1.86 % $ 2.66 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 58.47 4.37 % $ 1.68 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.5 1.56 % $ 308 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 15.47 1.91 % $ 2.08 B canadaCanada
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.9 0.24 % $ 270 M britainBritain
Beam Therapeutics Beam Therapeutics
BEAM
$ 26.75 0.91 % $ 2.65 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 67.36 0.99 % $ 12.9 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada